• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024

    8/6/24 7:00:00 AM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMRX alert in real time by email

    DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Tuesday, August 13, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business overview.

    To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 5436125. A live audio webcast of the call will also be available on the Investors' section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

    About Chimerix

    Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

    CONTACT:

    Will O'Connor

    Stern Investor Relations

    212-362-1200

    [email protected]



    Primary Logo

    Get the next $CMRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMRX

    DatePrice TargetRatingAnalyst
    5/23/2023$7.00Outperform
    Robert W. Baird
    9/7/2022$7.00Overweight
    CapitalOne
    12/22/2021$21.00 → $24.00Buy
    HC Wainwright & Co.
    11/22/2021$19.00 → $21.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CMRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Middleton Fred A bought $16,522 worth of shares (17,295 units at $0.96) (SEC Form 4)

    4 - CHIMERIX INC (0001117480) (Issuer)

    11/20/23 3:28:44 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Middleton Fred A bought $2,489 worth of shares (2,705 units at $0.92) (SEC Form 4)

    4 - CHIMERIX INC (0001117480) (Issuer)

    11/13/23 4:39:41 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Middleton Fred A bought $19,636 worth of shares (20,000 units at $0.98) (SEC Form 4)

    4 - CHIMERIX INC (0001117480) (Issuer)

    9/26/23 3:58:48 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

    Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member

    7/28/25 8:00:00 AM ET
    $CMRX
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

    New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2024. "The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chi

    3/21/25 6:00:00 AM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4). The stock options have an exercise price per share equal to Chimerix's closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, wi

    3/7/25 4:01:00 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Vakiener Victoria

    4 - CHIMERIX INC (0001117480) (Issuer)

    4/21/25 4:17:40 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Sherman Michael A. returned $3,620,138 worth of shares to the company (423,408 units at $8.55), closing all direct ownership in the company (SEC Form 4)

    4 - CHIMERIX INC (0001117480) (Issuer)

    4/21/25 4:16:42 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO and CCO Riga Thomas J returned $520,079 worth of shares to the company (60,828 units at $8.55), closing all direct ownership in the company (SEC Form 4)

    4 - CHIMERIX INC (0001117480) (Issuer)

    4/21/25 4:15:59 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRX
    SEC Filings

    View All

    SEC Form 15-12G filed by Chimerix Inc.

    15-12G - CHIMERIX INC (0001117480) (Filer)

    5/1/25 8:51:45 AM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Chimerix Inc.

    EFFECT - CHIMERIX INC (0001117480) (Filer)

    4/23/25 12:15:12 AM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Chimerix Inc.

    S-8 POS - CHIMERIX INC (0001117480) (Filer)

    4/21/25 4:54:30 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on Chimerix with a new price target

    Robert W. Baird initiated coverage of Chimerix with a rating of Outperform and set a new price target of $7.00

    5/23/23 7:29:20 AM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CapitalOne initiated coverage on Chimerix with a new price target

    CapitalOne initiated coverage of Chimerix with a rating of Overweight and set a new price target of $7.00

    9/7/22 8:57:44 AM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Chimerix with a new price target

    HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $24.00 from $21.00 previously

    12/22/21 6:12:39 AM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRX
    Leadership Updates

    Live Leadership Updates

    View All

    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

    Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member

    7/28/25 8:00:00 AM ET
    $CMRX
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chimerix Appoints Marc D. Kozin to Board of Directors

    DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company's Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company's 2024 Annual Meeting of Stockholders in June, after ten years of service. "We are pleased to welcome Marc to the Board of Directors. Marc's strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we wo

    3/21/24 7:00:00 AM ET
    $CMRX
    $UFPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Chimerix Appoints Lisa Decker to Board of Directors

    DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors. Ms. Decker replaces Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring from the Chimerix Board after nearly 10 years of service. "We are delighted to welcome Lisa to the Chimerix Board of Directors. She brings a wealth of scientific expertise, oncology drug development and business development experience that will be important assets to

    12/29/23 7:00:00 AM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRX
    Financials

    Live finance-specific insights

    View All

    Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

    New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2024. "The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chi

    3/21/25 6:00:00 AM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

    Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recu

    12/9/24 4:01:00 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

    – Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review – – Alignment with TGA to Submit Dordaviprone for Provisional Approval in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2024 and provided an operational update. "We have sustaine

    11/7/24 7:00:00 AM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

    SC 13G/A - CHIMERIX INC (0001117480) (Subject)

    2/14/24 5:01:40 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

    SC 13G/A - CHIMERIX INC (0001117480) (Subject)

    2/12/24 6:06:37 AM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Chimerix Inc.

    SC 13G - CHIMERIX INC (0001117480) (Subject)

    9/29/23 4:54:06 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care